Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234891 | 0.82 | HPGD (0.44) | HPGDTSHRMITFALDH1A1TP53 | |
| SCHEMBL13184146 | 0.76 | MAPT (0.45) | HPGDTSHR | |
| SCHEMBL21847663 | 0.72 | JAK2 (0.32) | — | |
| SCHEMBL22164239 | 0.71 | — | — | |
| SCHEMBL14012129 | 0.71 | HCAR2 (0.47) | TP53 | |
| SCHEMBL18704564 | 0.70 | ADORA3 (0.53) | CDK8CDK5CLK4HPGDTSHR | |
| SCHEMBL22164238 | 0.69 | LMNA (0.31) | HPGD | |
| SCHEMBL22164240 | 0.69 | — | — | |
| SCHEMBL24759495 | 0.68 | HCAR2 (0.47) | — | |
| SCHEMBL30607554 | 0.68 | HCAR2 (0.50) | CYP2C19HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275739-B2 | Inhibitors of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11845753-B2 | Inhibitors of menin-mll interaction | BIOMEA FUSION, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220024936-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024936-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2022-01-27 | — | — | US | disclosed |
| US-11174263-B2 | Inhibitors of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174263-B2 | Inhibitors of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3906029-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Biomea Fusion, LLC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20200255434-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200255434-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2020-08-13 | — | — | US | disclosed |
| WO-2020142559-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, LLC (US) | 2020-07-09 | — | — | WO | disclosed |
| US-9499519-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499519-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9422267-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422267-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014105958-A2 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275739-B2 | Inhibitors of menin-MLL interaction | MLLT1, MEN1, MLLT3 | CDK8 296/4885CDK5 976/4885CLK4 2714/4885 |
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, FGFR3, FGFR1 | CDK8 127/4885CDK5 213/4885CLK4 681/4885 |
| US-11174263-B2 | Inhibitors of menin-MLL interaction | MLLT1, MEN1, MLLT3 | CDK8 462/4885CDK5 1407/4885CLK4 2347/4885 |
| US-20200255434-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CDK8 296/4885CDK5 976/4885CLK4 2714/4885 |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, IPMK, IP6K2 | CDK8 75/4885CDK5 110/4885CLK4 610/4885 |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CDK8 296/4885CDK5 976/4885CLK4 2714/4885 |
| US-20220024936-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CDK8 296/4885CDK5 976/4885CLK4 2714/4885 |
| US-11845753-B2 | Inhibitors of menin-mll interaction | MLLT1, MEN1, MLLT3 | CDK8 296/4885CDK5 976/4885CLK4 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.